Citi raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $84 from $69 and keeps a Buy rating on the shares. The firm says the company announced “home run results” for Tryngolza in severe hypertriglyceridemia. Citi sees additional upside in the shares with the drug positioned to become a blockbuster.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharmaceuticals: Promising Pipeline and Potential Profitability Drive Buy Rating
- Ionis Pharmaceuticals upgraded to Outperform from Market Perform at BMO Capital
- Promising Investment: Ionis Pharmaceuticals’ Olezarsen Surpasses Expectations with Phase 3 CORE Trial Success
- Why Did IONIS Stock (IONS) Surge to a Four-Year High?
- Ionis Pharmaceuticals price target raised to $78 from $58 at Barclays